- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy ×
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
RAFT: A CRISPR-Free RNA Trans-Splicing Platform for MYH7 Correction in Hypertrophic Cardiomyopathy
Unmet Need Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease affecting 1 in 500 individuals, frequently caused by mutations in the MYH7 gene. Current gene therapy approaches, including AAV-based gene replacement, face significant challenges…
Chimeric AAV vectors enabling antibody evasion and redosing for cardiac gene therapy
Unmet Need Gene therapy using adeno-associated virus (AAV) vectors is severely limited by pre-existing immunity in 30–80% of adults and by the development of neutralizing antibodies after initial treatment, preventing redosing. There is a critical…
Rationally designed chimeric AAV capsids for enhanced immune evasion, cellular uptake, and transduction efficiency
Unmet Need Adeno-associated virus (AAV) vectors are a leading platform for in vivo gene therapy, yet their clinical potential is limited by key biological barriers. Pre-existing immunity to common AAV serotypes diminishes vector efficacy and…
Muscle-targeted gene therapy for SLC25A4 mitochondrial deficiency
Unmet Need There is a significant unmet need for disease-modifying therapies that address mitochondrial dysfunction in inherited cardiomyopathies and myopathies such as SLC25A4 deficiency. Existing treatments are limited to supportive care and heart transplantation, with…
RNA switch enabling stress-responsive regulation of protein expression for safer, more consistent gene and mRNA therapies
Unmet Need Current gene and mRNA therapies lack mechanisms to regulate protein expression in response to intracellular stress. Overexpression of therapeutic proteins can induce ER stress leading to unfolded proteins that do more harm than…
Novel AAV capsid variants for CNS-targeted gene therapies
Unmet Need The development of effective gene therapies for central nervous system (CNS) diseases faces a critical bottleneck: current adeno-associated virus (AAV) vectors lack sufficient transduction efficiency and specificity for human brain cells. Standard AAV…
Methods and compositions for enhancing viral and mRNA gene therapy with engineered RNA elements
Unmet Need An outstanding challenge in creating effective gene therapies, particularly those based on adeno-associated virus (AAV) and mRNA delivery platforms, is overcoming sub-optimal transgene expression. Inefficiencies in translation and stability of therapeutic gene products…
A novel all-in-one AAV system for efficient epigenome editing in neurodegenerative diseases
Unmet Need Neurodegenerative diseases such as Alzheimer’s and Parkinson’s affect over 55 million people worldwide, with prevalence expected to double by 2050 due to aging populations. These conditions are progressive, debilitating, and currently have no…
Permanent blood pressure control through liver-directed gene editing
Unmet Need The World Health Organization estimates that high blood pressure (hypertension) results in approximately 9 million annual deaths worldwide. While current medications can lower blood pressure, they are limited by the need for lifelong…
Gene therapy for ATP1A3-Related Neurologic Disorders
Unmet Need Alternating Hemiplegia of Childhood (AHC) is a rare neurologic disorder affecting children, causing episodes of temporary paralysis, dystonia, and severe behavioral issues, with prevalence estimates ranging from 1 in 1 million to 1…
Novel epigenome editors for multiplexed gene regulation
Unmet Need Epigenome editors activate or inhibit gene expression without modifying the underlying DNA sequence. Consequently, these editors can reversibly fine-tune gene expression without the risk of permanently altering the genome or off-target editing. Epigenome…
Splice switching oligonucleotides to restore PHKG2 expression in glycogen storage disease IX
Unmet Need Glycogen Storage Disease IX (GSD IX) is a rare inherited disorder primarily caused by mutations in the PHKG2 gene, leading to significant deficiencies in glycogen metabolism. Patients typically present with a variety of…